Components
Community claim
Additional appetite or weight effect.
Community and market provenance
Community mention, not clinical evidence
- Source: pdf01 · Page 5
- Source: pdf05 · Page 5
- Source: pdf08 · Page 1
- Source: pdf09 · Page 3
Evidence of the exact combination
No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.
Component links are not combination evidence. A commercial name’s composition may vary.
Uncertainty and risks
Overlapping metabolic effects and gastrointestinal intolerance are plausible concerns. The combination cannot inherit results from CagriSema; supplier codes alone may be ambiguous.
Observed in supplier/community material; prevalence not quantified.
No dosing or mixing instructions are provided.
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-MOU
October 16, 2026
- PMID35658024
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators.
October 16, 2026
- PMID37366315
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators.
October 16, 2026
- PMID42810372
Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A.
October 16, 2026
- R28
- R29
- R30
- REG-ZEP
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026